Hepatitis C virus infection in nonliver solid organ transplant candidates and recipients

Bashar A. Aqel, Hugo E Vargas

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

PURPOSE OF REVIEW: Transplantation is the best treatment for many patients with end-stage organ failure. Hepatitis C infection is prevalent among solid organ candidates and recipients and continues to represent a major source of morbidity and mortality. Prior interferon (IFN)-based therapies have been associated with limited efficacy and high rates of adverse events. Furthermore, prior IFN-based regimens are associated with high rates of allograft rejection limiting their use post-transplant. This review will outline the limited experience with current treatment regimens and how to incorporate the new hepatitis C virus (HCV) treatment regimens.

RECENT FINDINGS: The introduction of new direct-acting antiviral (DAA) agents against HCV has dramatically altered the landscape of treatment for HCV. Different all-oral regimens are currently available and are rapidly becoming the standard for treating patients with chronic hepatitis C. Excluding patients with liver disease or those who received liver transplant, those regimens have not been studied in patients awaiting solid organ transplant, or those transplanted.

SUMMARY: The safety and efficacy of DAAs in patients awaiting liver transplant and liver transplant recipients provide us with some insight and guidance on how to use those all-oral IFN-free regimens to allow effective treatment for patients who received or are awaiting nonliver solid organ transplants.

Original languageEnglish (US)
Pages (from-to)259-266
Number of pages8
JournalCurrent Opinion in Organ Transplantation
Volume20
Issue number3
DOIs
StatePublished - Jun 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation

Cite this